News

CN Bio Innovations announces Hepatitis B research collaboration with leading pharmaceutical company

Welwyn Garden City, UK, 21st April 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with a third (undisclosed) pharmaceutical company. The research, which will take advantage of CN Bio’s full viral lifecycle… Read more »

READ MORE

CN Bio announces research collaboration with antisense discovery pioneers Isis Pharmaceuticals

CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with RNA based drug discovery and development company Isis Pharmaceuticals Inc. Research relevant to Isis’s innovative RNA targeting, antisense oligonucleotides will be performed at CN… Read more »

READ MORE

CN Bio announces opening of new Biosafety Level 3 facility

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK.  The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes… Read more »

READ MORE

NIH Director highlights LiverChip in Compton Lecture

Dr Francis S. Collins, Director of the US National Institutes of Health (NIH), highlighted LiverChip during the 2014 Karl Taylor Compton Lecture on October 28 at the Massachusetts Institute of Technology. In his lecture entitled “Exceptional Opportunities in Biomedical Research” Collins featured work by MIT Professor Linda Griffith, S.E.T.I. Professor of Biological and Mechanical Engineering… Read more »

READ MORE

TSB Funds New Research by CN Bio into Fatty Liver Disease

CN Bio Innovations (CN Bio) announced today the receipt of a 12 months funding award from the UK’s Technology Strategy Board (TSB) for the development of human in vitro models of Non-Alcoholic Fatty Liver Disease (NAFLD). CN Bio will partner on the award with UK-based CRO Xenogesis Ltd., which specialises in preclinical DMPK, quantitative bioanalysis… Read more »

READ MORE

Imperial College London to present first public HBV data from CN Bio in vitro liver model

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has announced that data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be the subject of oral and poster presentations… Read more »

READ MORE

CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London

Collaboration will develop and further validate CN Bio’s in vitro model of Hepatitis B liver infection Oxford, UK, 28 July 2014: CN Bio Innovations Ltd (CN Bio), an expert in developing leading edge human biomimetic platforms to test and develop therapeutics for serious diseases, announced today that it has signed a research agreement with Imperial… Read more »

READ MORE

Promotion of Dr David Hughes to the role of Chief Technology Officer

Dr David Hughes has been promoted to the role of Chief Technology Officer, effective immediately. In his new role, he will take responsibility for overseeing management of all technical projects and alliances with CN Bio partners. He will also continue to manage the internal scientific and engineering teams. Dr Hughes joined the Company in 2010… Read more »

READ MORE

CN Bio appoints Professor Mark Thursz as Scientific Advisor

CN Bio Innovations (CN Bio) today announced the appointment of Professor Mark Thursz as a scientific advisor to the company. “Mark has considerable experience and a deep knowledge of clinical hepatology and related non-clinical research and I believe that CN Bio will benefit from having access to Mark’s expertise as we continue to develop and… Read more »

READ MORE

CN Bio hires Director of Licensing

CN Bio Innovations (CN Bio) announced today the appointment of Gavin Clark to the role of Director of Licensing. This is a new position created to facilitate the commercialization of CN Bio’s novel proprietary infectious disease models. Gavin brings with him over 35 years of experience in the pharmaceutical industry including roles as Global Licensing… Read more »

READ MORE

Liver disease to become a bigger killer than heart disease or cancer

Liver disease has the potential to become the UK’s biggest killer within a generation, is the stark assessment of an independent report released today by a group of politicians and liver experts. The damning report highlights the “scandalous” absence of a national strategy to tackle liver disease, the result of which is a “shameful waste of… Read more »

READ MORE

Zyoxel Ltd to become CN Bio Innovations Ltd

Zyoxel, an expert in advanced in vitro 3D liver models for drug discovery and drug testing, has today announced it is changing its name to CN Bio Innovations Ltd  (CNBIO). The move is part of a strategic rebrand designed to closer align the organisation with its Hong Kong-based holding company, CN Innovations Holdings Limited (CNI)…. Read more »

READ MORE